LOW DOSE (greater than or equal to 2‐<4 mg/day) showed no clear difference in leaving the study early: any reason ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).
It is very uncertain whether intensive counseling changes continuation of hormonal contraceptive method compared with usual family planning care (very low certainty).
The review found no eligible studies for this question.
Intensive counseling may leads to lower rate of discontinuation due to menstrual disturbances compared with usual family planning care (low certainty).
Intensive counseling showed no clear difference in rate of discontinuation due to all other adverse events compared with usual family planning care (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether intensive counseling changes pregnancy compared with usual family planning care (very low certainty).
It is very uncertain whether reminders (+/‐ educational information) changes continuation of hormonal contraceptive method compared with usual family planning care (very low certainty).
The review found no eligible studies for this question.
Reminders (+/‐ educational information) showed no clear difference in adherence to method use as indicated by on‐time injections overall compared with usual family planning care (low certainty).
Moxifloxacin‐containing 4‐month ATT regimens probably leads to higher relapse compared with standard 6‐month ATT regimen (moderate certainty).
Gatifloxacin‐containing 4‐month ATT regimens showed no clear difference in serious adverse events compared with standard 6‐month ATT regimens (moderate certainty).
Moxifloxacin‐containing 4‐month ATT regimens showed no clear difference in death from any cause compared with standard 6‐month ATT regimen (moderate certainty).
Moxifloxacin‐containing 4‐month ATT regimens showed no clear difference in treatment failure compared with standard 6‐month ATT regimen (moderate certainty).
Moxifloxacin‐containing 4‐month ATT regimens showed no clear difference in acquired drug resistance compared with standard 6‐month ATT regimen (low certainty).
Moxifloxacin‐containing 4‐month ATT regimens showed no clear difference in serious adverse events compared with standard 6‐month ATT regimen (moderate certainty).
Gatifloxacin‐containing 4‐month ATT regimens probably leads to higher relapse compared with standard 6‐month ATT regimens (moderate certainty).
Gatifloxacin‐containing 4‐month ATT regimens showed no clear difference in death from any cause compared with standard 6‐month ATT regimens (moderate certainty).
Gatifloxacin‐containing 4‐month ATT regimens showed no clear difference in treatment failure compared with standard 6‐month ATT regimens (moderate certainty).